Cooper Companies (COO) stock plummeted 5.39% in the intraday trading session on Friday, following mixed first-quarter results that prompted several analysts to lower their price targets and ratings on the medical device maker.
After reporting a revenue shortfall but an earnings beat for Q1 2025, Cooper Companies faced a wave of price target cuts from Wall Street firms. Citi lowered its target to $110 from $115 while maintaining a Buy rating, while Baird cut its target to $107 from $117 and reiterated an Outperform rating.
Morgan Stanley analysts maintained a Hold rating on the stock, noting challenges and opportunities ahead for the company. JPMorgan also trimmed its price target to $110 from $120 but kept an Overweight rating, while Needham reiterated a Hold stance, citing Cooper's mixed Q1 performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.